全文获取类型
收费全文 | 13872篇 |
免费 | 1004篇 |
国内免费 | 297篇 |
专业分类
耳鼻咽喉 | 343篇 |
儿科学 | 146篇 |
妇产科学 | 154篇 |
基础医学 | 2119篇 |
口腔科学 | 172篇 |
临床医学 | 1083篇 |
内科学 | 2810篇 |
皮肤病学 | 601篇 |
神经病学 | 1006篇 |
特种医学 | 836篇 |
外国民族医学 | 3篇 |
外科学 | 1940篇 |
综合类 | 245篇 |
一般理论 | 7篇 |
预防医学 | 437篇 |
眼科学 | 403篇 |
药学 | 1382篇 |
1篇 | |
中国医学 | 283篇 |
肿瘤学 | 1202篇 |
出版年
2023年 | 72篇 |
2022年 | 99篇 |
2021年 | 396篇 |
2020年 | 289篇 |
2019年 | 402篇 |
2018年 | 469篇 |
2017年 | 386篇 |
2016年 | 554篇 |
2015年 | 835篇 |
2014年 | 942篇 |
2013年 | 997篇 |
2012年 | 1500篇 |
2011年 | 1408篇 |
2010年 | 885篇 |
2009年 | 764篇 |
2008年 | 936篇 |
2007年 | 869篇 |
2006年 | 727篇 |
2005年 | 659篇 |
2004年 | 497篇 |
2003年 | 408篇 |
2002年 | 375篇 |
2001年 | 105篇 |
2000年 | 71篇 |
1999年 | 72篇 |
1998年 | 50篇 |
1997年 | 57篇 |
1996年 | 28篇 |
1995年 | 30篇 |
1994年 | 31篇 |
1993年 | 18篇 |
1992年 | 36篇 |
1991年 | 28篇 |
1990年 | 25篇 |
1989年 | 22篇 |
1988年 | 9篇 |
1987年 | 11篇 |
1986年 | 14篇 |
1985年 | 8篇 |
1984年 | 16篇 |
1983年 | 10篇 |
1982年 | 4篇 |
1981年 | 12篇 |
1980年 | 5篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1974年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
So Young Jeon Oh Eun Kwon Jin Woo Jang Sang Yoon Kang Jin-Young Min Sung Wan Kim 《Auris, nasus, larynx》2021,48(5):1031-1034
Stickler syndrome is a genetic disorder of connective tissue. One of the major symptoms associated with this disorder is an oro-facial malformation, which may cause a submucous cleft or a complete cleft of the hard palate. A 32-year-old man diagnosed with Stickler syndrome and a submucosal cleft palate (SMCP) visited our hospital with a chief complaint of excessive daytime sleepiness. The patient was diagnosed with severe obstructive sleep apnea (OSA), and administration of a polysomnography test revealed an apnea-hypopnea index (AHI) of 30.9 events/hour (h). Auto-titrating continuous positive airway pressure was initiated to control the OSA symptoms and subsequently the patient showed some improvement. However, due to continuous velopharyngeal insufficiency symptoms, intravelar veloplasty was performed. Three months after surgery, the AHI had decreased to 12.4 events/h. Recent studies have described a greater risk for OSA in individuals with cleft palate, than in the general population. The present case demonstrates surgical success in a patient with OSA and SMCP, suggesting that palatal surgery may be considered an optional surgical treatment for OSA patients with SMCP. 相似文献
2.
Hakmin Lee Minseung Lee Seok-Soo Byun Sang Eun Lee Sung Kyu Hong 《Clinical genitourinary cancer》2019,17(1):e221-e226
Introduction
The American Joint Committee on Cancer (AJCC) tumor, node, metastasis classification system (TNM) staging manual has been updated and provides more specified stage grouping for prostate cancer (PCa). We aimed to validate the updated AJCC stage groups for PCa using a radical prostatectomy (RP) cohort.Patients and Methods
We analyzed the data of 3032 patients previously treated with RP for localized PCa. We stratified patients into stage groups according to the 8th edition of the AJCC manual and compared biochemical recurrence (BCR)-free survival using Kaplan-Meier analyses.Results
There were 217 patients in stage group I, 33 in IIA, 1101 in IIB, 535 in IIC, 129 in IIIA, 781 in IIIB, and 236 in IIIC. There were no significant differences in BCR-free survival between stage groups IIC and IIIA (P = .875). Subsequently, the low–Gleason score (GS) IIIA subgroup (GS ≤ 3 + 4, P = .025) showed superior BCR-free survival than the IIC group, and the high-GS IIIA subgroups (GS ≥ 4 + 3, P = .004) showed a poorer BCR-free survival than the IIC group. Furthermore, there were no significant differences between groups I and IIA (P = 330) and between groups IIA and IIB (P = .942). Our new staging system provided a better ability to discriminate the prognosis of each group. However, our study has several limitations, such as retrospective design, relatively short follow-up period, and need for further validation.Conclusion
The current AJCC prognostic groups show some contradictory results, particularly concerning prognosis of the IIC and IIIA groups. We suggest that GS be given more weight than serum prostate-specific antigen level in stage group stratification. 相似文献3.
Youjin Kim Chu Hyun Kim Ho Yun Lee Se-Hoon Lee Hong Sook Kim Sook Lee Hongui Cha Sungjun Hong Kyunga Kim Sang Won Seo Jong-Mu Sun Myung-Ju Ahn Jin Seok Ahn Keunchil Park 《Journal of thoracic oncology》2019,14(9):1608-1618
IntroductionHyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression after immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristics of HPD and investigate its predictive markers.MethodsClinical and radiological findings of 335 patients with advanced NSCLC treated with ICI monotherapy were retrospectively analyzed. Radiological data were quantitatively and longitudinally analyzed for tumor size and volume by comparing baseline and follow-up computerized tomography results. The findings were matched with individual genomic profiles generated by deep sequencing of 380 genes.ResultsAmong 135 patients with progressive disease (PD), as assessed by the Response Evaluation Criteria in Solid Tumors version 1.1 criteria, 48 (14.3% of all patients and 35.6% of those with PD) and 44 (13.1% of all patients and 32.6% among those with PD) were found to have HPD by volumetry (HPDV) and assessed by RECIST 1.1 (HPDR), respectively. Patients with HPDV were associated with significantly inferior overall survival (OS) versus that of patients without HPDV with PD (median OS = 4.7 months [95% confidence interval: 3.5–11.9)] versus 7.9 months [95% confidence interval: 6.0–13.5] [p = 0.004]); OS did not differ between patients without and without HPDR. HPDV status was an independent factor in OS. A derived neutrophil-to-lymphocyte ratio greater than 4 and lactate dehydrogenase level greater than the upper limit of normal were significantly associated with HPDV. Moreover, we identified coinciding KRAS and serine/threonine kinase 11 gene (STK11) mutations in the cohort of patients with HPDV (three of 16), whereas none were found in the cohort of patients without HPDV (zero of 28).ConclusionsDefining HPD treated with ICI on the basis of volumetric measurement is more precise than is defining it on the basis of one-dimensional analysis. Pre-ICI derived neutrophil-to-lymphocyte ratio, lactate dehydrogenase level, and concurrence of STK11 and KRAS mutations could thus be used as potential biomarkers for HPD prediction. 相似文献
4.
Sang Kim Samuel DeMaria Jiawen Li Hung‐Mo Lin Natalie Smith David Wax Bryan Hill Ashley So Parissa Tabrizian Sander Florman Dennis Feierman Jeron Zerillo 《Clinical transplantation》2019,33(3)
During liver transplantation, the patient is at risk of developing progressive lactic acidosis. Following reperfusion, correction of acidosis may occur. In some patients, acidosis will worsen, a phenomenon referred to as persistent acidosis after reperfusion (PAAR). We compared postoperative outcomes in patients who manifested PAAR vs those that did not. All adult patients undergoing liver transplantation from 2002 to 2015 were included. PAAR is defined by the presence of a significant negative slope coefficient for base excess values measured after hepatic artery anastomosis through 72 hours postoperatively. Primary outcome was a composite of 30‐day and in‐hospital mortality. Secondary outcomes included: ICU LOS, total hospital LOS, and re‐transplantation rate within 7 days. PAAR occurred in 10% of the transplant recipients. Patients with PAAR had higher MELD, BMI, and eGFR and demonstrated a longer median ICU LOS and hospital median LOS with a trend toward mortality difference. But, after propensity matching, the mortality rate difference became significantly higher in patients with PAAR compared with matched controls while the ICU LOS differences disappeared. The re‐transplantation rates were similar also between the PAAR and no PAAR groups. The cohort with PAAR had a significant 30‐day and in‐hospital increase in mortality after propensity score matching. 相似文献
5.
6.
BackgroundThe efficacy and safety of etanercept in the treatment of psoriasis has been proven, and the drug was approved for the treatment of moderate to severe psoriasis. However, there have been few studies that have presented real-world data focused on concomitant treatment during etanercept treatment, and the switching pattern after discontinuation of etanercept.ObjectiveTo reveal the real-world treatment pattern of etanercept-based psoriasis treatment and to investigate the switching pattern after withdrawal of etanercept.MethodsWe enrolled 66 patients with psoriasis who were treated with etanercept. We collected data regarding the demographic characteristics of the patients, etanercept treatment schedules, and other treatments administered during the etanercept treatment period. We also investigated the treatment pattern after the discontinuation of etanercept with emphasis on the drug-free interval and the administered treatment modalities.ResultsThe mean treatment duration was 22.7±26.1 months and the mean number of etanercept injections was 21.5±27.9. Thirty-six patients were administered concomitant systemic medication or phototherapy. After discontinuation of etanercept, 54 patients were followed up and 34 of these patients were administered other systemic medication or phototherapy; phototherapy and cyclosporine was the most commonly administered treatment modality and 27.4% of treatments used biologics.ConclusionThe treatment schedule for etanercept was modified according to the severity of psoriasis and concomitant treatment was administered to improve the effectiveness of treatment in the patients enrolled in the study. We also found that most patients required other treatment modalities to control psoriasis during the period of etanercept treatment. 相似文献
7.
8.
9.
10.